Liquidia Corporation
LQDA
$77.70
+4.38%
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for pulmonary hypertension (PH), leveraging its proprietary PRINT particle engineering platform to create uniform drug particles. The company's lead product, YUTREPIA (treprostinil) inhalation powder, targets pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease, positioning it as a specialized player in the rare disease space. Currently, the stock is drawing attention due to a remarkable revenue surge, driven by YUTREPIA's commercial uptake, and the market is closely watching the potential of its pipeline candidate, L606, a liposomal treprostinil formulation. The company's recent financial turnaround—from losses to profitability—has fueled investor optimism, though questions remain about sustainability and competitive dynamics in the PH market.…
LQDA
Liquidia Corporation
$77.70
Investment Opinion: Should I buy LQDA Today?
We rate LQDA a Buy, driven by the company's exceptional revenue growth and recent profitability inflection. The analyst consensus is Buy with an average target of $107.75, implying 44.7% upside. The thesis is that YUTREPIA's rapid adoption and high gross margins will continue to drive earnings growth, justifying the forward PE of 13.18x.
Sign up to view all
LQDA 12-Month Price Forecast
The AI assessment is bullish, driven by the company's explosive revenue growth and recent profitability. The forward PE of 13.18x is attractive relative to the growth rate, and analyst sentiment is strongly positive. However, the high valuation and competitive risks warrant a medium confidence. The stance would be upgraded if revenue growth accelerates further or if L606 shows positive data, and downgraded if growth decelerates or the company faces a major competitive setback.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Liquidia Corporation's 12-month outlook, with a consensus price target around $107.75 and implied upside of +38.7% versus the current price.
Average Target
$107.75
0 analysts
Implied Upside
+38.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $130
Analyst target range
The target price range spans from a low of $90.00 to a high of $130.00, indicating a wide spread of $40, which reflects moderate uncertainty about the company's future performance. The low target of $90 still implies a +20.9% upside, suggesting that even the most bearish analyst sees value, while the high target of $130 implies a +74.6% upside, likely assuming continued market share gains and successful pipeline development. The recent ratings history shows a series of Buy and Strong Buy actions from firms like HC Wainwright, Needham, and BTIG, with no downgrades, reinforcing the positive sentiment. This pattern suggests that analysts are confident in the company's trajectory, though the wide target range indicates that the magnitude of success is still debated.
Drowning in data?
Find the real signal!
Bulls vs Bears: LQDA Investment Factors
Liquidia presents a compelling bull case driven by explosive revenue growth, a recent profitability inflection, and strong analyst support. The bear case centers on extreme valuation, high leverage, and single-product concentration. Currently, the bull case has stronger evidence given the accelerating revenue trajectory and positive earnings surprise, but the stock's valuation leaves little room for error. The most critical tension is whether YUTREPIA can sustain its rapid market share gains against competitive pressures and whether the company can maintain profitability while scaling. If growth decelerates or competition intensifies, the stock could face significant downside despite the positive momentum.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged to $132.865M, up 41.58% YoY and a dramatic acceleration from $3.12M in Q1 2025. Sequential growth from $92.021M in Q4 2025 to $132.865M in Q1 2026 demonstrates rapid YUTREPIA adoption.
- Profitability Inflection Achieved: The company turned profitable with Q1 2026 net income of $52.862M and EPS of $0.60, a stark contrast to the -$38.367M loss in Q1 2025. This inflection validates the commercial model and supports the forward PE of 13.18x.
- Strong Analyst Conviction: All 8 analysts rate the stock Buy or Strong Buy (mean 1.625), with an average target of $107.75, implying 44.7% upside from the current price of $74.44. No downgrades have been issued recently.
- High Gross Margins: Gross margin reached 90.86% in Q1 2026, reflecting the low cost of goods for inhaled treprostinil. This high margin provides significant operating leverage as revenue scales.
Bearish
- Extreme Valuation Risk: The stock trades at 18.75x sales and 66.33x book value, with a PEG of 0.83 based on forward estimates. Any growth disappointment could trigger a sharp de-rating, especially after a 185% 1-year rally.
- High Debt-to-Equity: Debt-to-equity stands at 4.42, indicating significant leverage. While current ratio is 1.40, the high debt load increases financial risk if revenue growth stalls or interest rates rise.
- Revenue Concentration in YUTREPIA: YUTREPIA accounts for nearly all product revenue ($129.881M of $132.865M in Q1 2026). Dependence on a single product makes the company vulnerable to competitive entry, regulatory setbacks, or supply disruptions.
- Competitive Threats from United Therapeutics: United Therapeutics markets Tyvaso DPI, a direct competitor in inhaled treprostinil. Litigation and market share battles could pressure YUTREPIA's growth trajectory and pricing.
LQDA Technical Analysis
Liquidia's stock has been in a powerful uptrend over the past year, with a 1-year price change of +185.32%, far outpacing the S&P 500's +20.37%. The current price of $74.44 sits near the upper end of its 52-week range, at approximately 79.5% of the range (calculated as (74.44-21.15)/(93.61-21.15)), indicating strong momentum and bullish sentiment. This positioning near the highs suggests the market is rewarding the company's execution, though it also raises the risk of overextension, especially after such a steep run.
Beta
0.57
0.57x market volatility
Max Drawdown
-35.7%
Largest decline past year
52-Week Range
$21-$94
Price range past year
Annual Return
+199.4%
Cumulative gain past year
| Period | LQDA Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +4.0% |
| 3m | +29.5% | +5.3% |
| 6m | +122.3% | +12.6% |
| 1y | +199.4% | +20.1% |
| ytd | +147.5% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LQDA Fundamental Analysis
Liquidia's revenue trajectory has been nothing short of explosive. In Q1 2026, revenue reached $132.865 million, a 41.58% year-over-year increase from the prior year's quarter, and a dramatic acceleration from the $3.12 million reported in Q1 2025. This growth is driven by YUTREPIA's commercial launch, with product revenue of $129.881 million and service revenue of $2.984 million in the latest quarter. The sequential trend is equally impressive: revenue jumped from $8.837 million in Q2 2025 to $54.342 million in Q3 2025, then to $92.021 million in Q4 2025, and finally to $132.865 million in Q1 2026, indicating a rapid ramp-up in sales. This trajectory underscores the strong market adoption of YUTREPIA and the company's ability to execute on its commercial strategy.
Quarterly Revenue
$132865000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
90.9%
Latest Quarter
Free Cash Flow
$41147000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LQDA Overvalued?
Given that Liquidia has turned profitable, the PE ratio is the most appropriate valuation metric. The trailing PE is -43.11x (due to historical losses), but the forward PE is 13.18x, reflecting the market's expectation of sustained earnings growth. The PEG ratio of 0.83 suggests the stock is reasonably priced relative to its growth rate, implying that the market expects robust earnings expansion to justify the current valuation. The gap between the negative trailing PE and the positive forward PE highlights the company's recent inflection to profitability, which is a key driver of the stock's re-rating.
PE
-43.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-68.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial. The company carries a debt-to-equity ratio of 4.42, indicating heavy leverage that could strain cash flows if revenue growth falters. While the current ratio of 1.40 provides some liquidity buffer, the negative free cash flow (PCF -83.17x) and reliance on external financing heighten vulnerability. The recent profitability is encouraging, but the net margin of -43.53% on a trailing basis shows that losses are not fully behind. Any increase in interest rates or tightening credit conditions could increase borrowing costs and pressure the balance sheet. Additionally, the company's high valuation (PS 18.75x) leaves no room for earnings misses, as any disappointment could trigger a sharp sell-off.
